
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7342071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanomedicine Scale-up Technologies: Feasibilities and Challenges. AAPS PharmSciTech, 2014, 15, 1527-1534.	3.3	221
2	Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems. Journal of Pharmaceutical Sciences, 2018, 107, 1741-1753.	3.3	117
3	Amorphous-State Characterization of Efavirenz—Polymer Hot-Melt Extrusion Systems for Dissolution Enhancement. Journal of Pharmaceutical Sciences, 2012, 101, 3456-3464.	3.3	103
4	Formulation of Controlled Release Gellan Gum Macro Beads of Amoxicillin. Current Drug Delivery, 2010, 7, 36-43.	1.6	99
5	Physicochemical Characterization of Efavirenz–Cyclodextrin Inclusion Complexes. AAPS PharmSciTech, 2009, 10, 81-87.	3.3	83
6	Resveratrolâ€loaded nanomedicines for cancer applications. Cancer Reports, 2021, 4, e1353.	1.4	74
7	Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. International Journal of Pharmaceutics, 2004, 271, 155-165.	5.2	67
8	Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 915-933.	1.6	59
9	In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS PharmSciTech, 2005, 6, E565-E572.	3.3	53
10	Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clinical Pharmacokinetics, 2018, 57, 1385-1398.	3.5	51
11	Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica, 2018, 48, 89-108.	1.1	49
12	Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. International Journal of Pharmaceutics, 2005, 288, 325-334.	5.2	48
13	The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. Journal of Controlled Release, 2003, 86, 49-57.	9.9	44
14	Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. AAPS PharmSciTech, 2005, 6, E573-E585.	3.3	43
15	In Situ Gel Formulation for Enhanced Ocular Delivery of Nepafenac. Journal of Pharmaceutical Sciences, 2018, 107, 3089-3097.	3.3	40
16	Effect of Cyclodextrins on the Complexation and Nasal Permeation of Melatonin. Drug Delivery, 2008, 15, 381-388.	5.7	39
17	Gefitinib–cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Development and Industrial Pharmacy, 2009, 35, 1113-1120.	2.0	37
18	Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety, 2020, 43, 711-725.	3.2	37

#	Article	IF	CITATIONS
19	Lipid Materials for Topical and Transdermal Delivery of Nanoemulsions. Critical Reviews in Therapeutic Drug Carrier Systems, 2014, 31, 429-458.	2.2	36
20	Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. European Journal of Pharmaceutical Sciences, 2010, 39, 164-174.	4.0	32
21	Assessment of skin irritation and molecular responses in rat skin exposed to nonane, dodecane and tetradecane. Toxicology Letters, 2004, 153, 255-266.	0.8	29
22	Evaluation of EpiDerm full thickness-300 (EFT-300) as an in vitro model for skin irritation: Studies on aliphatic hydrocarbons. Toxicology in Vitro, 2010, 24, 669-676.	2.4	29
23	Application of Extrusion-Based 3D Printed Dosage Forms in the Treatment of Chronic Diseases. Journal of Pharmaceutical Sciences, 2020, 109, 3551-3568.	3.3	29
24	Effect of Penetration Enhancers on the Transdermal Delivery of Bupranolol Through Rat Skin. Drug Delivery, 2005, 12, 165-169.	5.7	28
25	Effect of methyl substitution of benzene on the percutaneous absorption and skin irritation in hairless rats. Toxicology Letters, 2005, 159, 261-271.	0.8	27
26	In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDermâ,,¢ (EPI-200) cultured human skin and hairless rats. Toxicology Letters, 2006, 167, 85-94.	0.8	27
27	Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines. AAPS PharmSciTech, 2019, 20, 99.	3.3	27
28	Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology, 2007, 237, 77-88.	4.2	26
29	Percutaneous absorption and skin irritation upon low-level prolonged dermal exposure to nonane, dodecane and tetradecane in hairless rats. Toxicology and Industrial Health, 2004, 20, 109-118.	1.4	25
30	Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities. Pharmaceutics, 2021, 13, 960.	4.5	25
31	Polymeric and Lipid-Based Materials for Topical Nanoparticle Delivery Systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2010, 27, 419-459.	2.2	25
32	<i>In vitro</i> percutaneous absorption of genistein from topical gels through human skin. Drug Development and Industrial Pharmacy, 2011, 37, 498-505.	2.0	24
33	Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infectious Diseases, 2017, 49, 483-492.	2.8	24
34	Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II. Pharmaceutical Research, 2004, 21, 108-113.	3.5	23
35	Glass transitions in binary drug+polymer systems. Materials Letters, 2009, 63, 2666-2668.	2.6	23
36	The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. Frontiers in Pharmacology, 2017, 8, 267.	3.5	23

3

#	Article	IF	CITATIONS
37	Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. Journal of Drug Targeting, 2011, 19, 731-740.	4.4	22
38	Single-Step Preparation and Deagglomeration of Itraconazole Microflakes by Supercritical Antisolvent Method for Dissolution Enhancement. Journal of Pharmaceutical Sciences, 2011, 100, 2952-2965.	3.3	20
39	Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate. Drug Development and Industrial Pharmacy, 2012, 38, 571-576.	2.0	20
40	Development of a Sustained-Release Voriconazole-Containing Thermogel for Subconjunctival Injection in Horses. , 2017, 58, 2746.		20
41	Use of sorbitol as pharmaceutical excipient in the present day formulations – issues and challenges for drug absorption and bioavailability. Drug Development and Industrial Pharmacy, 2019, 45, 1421-1429.	2.0	19
42	Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica, 2017, 47, 1015-1026.	1.1	18
43	Improved Ocular Delivery of Nepafenac by Cyclodextrin Complexation. AAPS PharmSciTech, 2018, 19, 2554-2563.	3.3	18
44	Progress in Topical siRNA Delivery Approaches for Skin Disorders. Current Pharmaceutical Design, 2015, 21, 4594-4605.	1.9	16
45	Microemulsion and Microporation Effects on the Genistein Permeation Across Dermatomed Human Skin. AAPS PharmSciTech, 2018, 19, 3481-3489.	3.3	15
46	Stabilityâ€indicating HPLC method for acyclovir and lidocaine in topical formulations. Biomedical Chromatography, 2020, 34, e4751.	1.7	15
47	Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells. AAPS PharmSciTech, 2020, 21, 304.	3.3	15
48	Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles. International Journal of Nanomedicine, 2013, 8, 137.	6.7	14
49	Effect of Aging on the Dissolution Stability of Glibenclamide/β-Cyclodextrin Complex. Drug Development and Industrial Pharmacy, 1999, 25, 1215-1219.	2.0	13
50	Effect of Lipophilicity on Microneedle-Mediated Iontophoretic Transdermal Delivery Across Human Skin In Vitro. Journal of Pharmaceutical Sciences, 2013, 102, 3784-3791.	3.3	12
51	Percutaneous delivery of <b>î±</b> -melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. Journal of Drug Targeting, 2016, 24, 537-547.	4.4	12
52	The effect of occlusive and unocclusive exposure to xylene and benzene on skin irritation and molecular responses in hairless rats. Archives of Toxicology, 2005, 79, 294-301.	4.2	11
53	Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. Toxicology Letters, 2009, 185, 168-174.	0.8	11
54	Transdermal iontophoretic delivery of selegiline hydrochloride, <i>in vitro</i> . Journal of Drug Targeting, 2010, 18, 657-664.	4.4	11

#	Article	IF	CITATIONS
55	Enhanced Bioavailability of Boswellic Acid by Piper longum: A Computational and Pharmacokinetic Study. Frontiers in Pharmacology, 2020, 11, 551911.	3.5	11
56	pH-Sensitive Liposomes for Enhanced Cellular Uptake and Cytotoxicity of Daunorubicin in Melanoma (B16-BL6) Cell Lines. Pharmaceutics, 2022, 14, 1128.	4.5	11
57	Encapsulation of hydrophobic drugs in a copolymer: Glass transition behavior and miscibility evaluation. Polymer Engineering and Science, 2011, 51, 1456-1465.	3.1	10
58	Elucidating the anti-melanoma effect and mechanisms of Hispolon. Life Sciences, 2020, 256, 117702.	4.3	10
59	Dexamethasone eluting 3D printed metal devices for bone injuries. Therapeutic Delivery, 2020, 11, 373-386.	2.2	10
60	Stability and degradation profiles of Spantide II in aqueous solutions. European Journal of Pharmaceutical Sciences, 2006, 27, 158-166.	4.0	8
61	Cardiovascular effects of transdermally delivered bupranolol in rabbits: Effect of chemical penetration enhancers. Life Sciences, 2008, 82, 273-278.	4.3	8
62	Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences, 2017, 106, 1814-1820.	3.3	8
63	Flavonoids as Multi-Target Compounds: A Special Emphasis on their Potential as Chemo-adjuvants in Cancer Therapy. Current Pharmaceutical Design, 2020, 26, 1712-1728.	1.9	8
64	Effect of dopaminergic neurotoxin MPTP/MPP+ on coenzyme Q content. Life Sciences, 2008, 83, 92-95.	4.3	7
65	Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2021, 38, 1-38.	2.2	7
66	Enhancement of transdermal delivery of phenylbutazone from liposomal gel formulations through deer skin. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 388-392.	1.3	6
67	Pharmacokinetic evaluation of novel midazolam gel formulations following buccal administration to healthy dogs. American Journal of Veterinary Research, 2018, 79, 73-82.	0.6	6
68	Role of Ceramides in Drug Delivery. AAPS PharmSciTech, 2019, 20, 287.	3.3	6
69	Biphasic flux profiles of melatonin: The Yina€ Yang of transdermal permeation enhancement mediated by fatty alcohol enhancers**"Yin―and "Yang―describe opposing qualities in a phenomenon, which are in a dynamic equilibrium. Each advance (Yang) is followed by a retreat (Yin), and every fall (Yin) transforms into a rise (Yang). Any mutable phenomenon is a consequence of Yin and Yang Journal of	3.3	4
70	Pharmaceutical Sciences, 2010, 99, 209-218. Implication of Formulation Strategies on the Bioavailability of Selected Plant-Derived Hepatoprotectants. Critical Reviews in Therapeutic Drug Carrier Systems, 2017, 34, 489-526.	2.2	4
71	Recent Advancements of Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery. Pharmaceutical Nanotechnology, 2022, 10, 3-23.	1.5	4
72	Delignified wood aerogels as scaffolds coated with an oriented chitosan–cyclodextrin co-polymer for removal of microcystin-LR. RSC Advances, 2022, 12, 20330-20339.	3.6	4

#	Article	IF	CITATIONS
73	Pyrrolidones as Penetration Enhancers. , 2015, , 291-299.		3
74	Evaluation of non-crystalline cellulose as a novel excipient in solid dose products. Drug Development and Industrial Pharmacy, 2018, 44, 1512-1519.	2.0	3
75	Stabilityâ€indicating HPLC assay for lysine–proline–valine (KPV) in aqueous solutions and skin homogenates. Biomedical Chromatography, 2015, 29, 716-721.	1.7	2
76	Non-alcoholic Steatohepatitis (NASH) Drug Discovery – Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 481-495.	2.1	2
77	Evaluation of Cytotoxicity and Taste-Masking Effect of Selected Flavors on Dental Lidocaine HCl Injection. Pharmaceuticals, 2020, 13, 353.	3.8	2
78	Difluprednate-Hydroxypropyl-β-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 92-101.	1.4	2
79	Niosomal formulation of hydroxytyrosol, a polyphenolic antioxidant, for enhancing transdermal delivery across human cadaver skin. Pharmaceutical Development and Technology, 2022, , 1-9.	2.4	1